38.87

2.73% -1.09

After Hours: 38.87

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $38.87, with a volume of 1.29M. It is down -2.73% in the last 24 hours and up +3.82% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$39.96

Open:

$40.02

24h Volume:

1.29M

Relative Volume:

1.18

Market Cap:

$3.10B

Revenue:

Net Income/Loss:

$-237.22M

P/E Ratio:

-10.28

EPS:

-3.78

Net Cash Flow:

$-212.64M

1W Performance:

-2.46%

1M Performance:

+3.82%

6M Performance:

+38.38%

1Y Performance:

+87.51%

1-Day Range:

$38.73

$40.50

1-Week Range:

$37.28

$42.18

52-Week Range:

$17.86

$58.40

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2024-11-11

Latest SEC Filings

AKRO's Discussions on Twitter

Compare AKRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKRO Akero Therapeutics Inc	38.87	3.18B	0	-237.22M	-212.64M	-3.78
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-25	Upgrade	BofA Securities	Neutral → Buy
Jan-27-25	Reiterated	H.C. Wainwright	Buy
Nov-18-24	Initiated	Citigroup	Buy
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

04:36 AM

30,208 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Cubist Systematic Strategies LLC - MarketBeat

04:36 AM

03:48 AM

Northern Trust Corp Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

03:48 AM

May 16, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by MPM Bioimpact LLC - MarketBeat

May 16, 2025

May 15, 2025

Algert Global LLC Lowers Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

May 15, 2025

Orbimed Advisors LLC Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

May 15, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Holdings Trimmed by Janus Henderson Group PLC - MarketBeat

May 15, 2025

Dimensional Fund Advisors LP Grows Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

May 15, 2025

The Manufacturers Life Insurance Company Has $3.47 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

May 15, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Lessened by Fred Alger Management LLC - MarketBeat

May 15, 2025

Citigroup Issues Pessimistic Forecast for Akero Therapeutics (NASDAQ:AKRO) Stock Price - Defense World

May 15, 2025

May 14, 2025

Akero Therapeutics (NASDAQ:AKRO) Releases Earnings Results, Beats Estimates By $1.91 EPS - MarketBeat

May 14, 2025

Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target - TipRanks

May 14, 2025

Insider Sell: Akero Therapeutics Inc (AKRO) President and CEO An - GuruFocus

May 14, 2025

Balyasny Asset Management L.P. Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

May 14, 2025

May 13, 2025

Pfizer Dissolves Share Stake In Akero Therapeutics - marketscreener.com

May 13, 2025

Akero Therapeutics (AKRO): Citigroup Adjusts Price Target, Maintains Buy Rating | AKRO Stock News - GuruFocus

May 13, 2025

Jefferies maintains Buy on Akero stock, reiterates $75 target - Investing.com

May 13, 2025

Citi Adjusts Price Target for Akero Therapeutics (AKRO) Amid Tri - GuruFocus

May 13, 2025